Pancreatic Cancer Research

ResearcherNagoya University HospitalNo recent work listed

Masato Nagino

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8142-9287; OpenAlex author ID A5101806826. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
65
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 2 papers · 2017: none · 2018: 3 papers · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 2 papers

Papers 11

  1. Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer: A Phase II Open-label Multicenter Prospective Tri… Co-author DOI 10.1097/sla.0000000000004535↗
  2. Prognostic Significance of Intraoperative Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma: A Single-Center Experience and Systemat… Co-author DOI 10.1245/s10434-022-11722-x↗
  3. Tumor marker recovery rather than major pathological response is a preferable prognostic factor in patients with pancreatic ductal adenocarcinoma with preopera… Co-author DOI 10.1002/jhbp.748↗
  4. Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy. Co-author DOI 10.1111/cas.14258↗
  5. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 … Co-author DOI 10.18999/nagjms.81.2.233↗
  6. Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer. Co-author DOI 10.1007/s00280-018-3554-3↗
  7. Pathologic Evaluation of Surgical Margins in Pancreatic Cancer Specimens Using Color Coding With Tissue Marking Dyes. Last author DOI 10.1097/mpa.0000000000001106↗
  8. Microscopic Venous Invasion in Pancreatic Cancer. Co-author DOI 10.1245/s10434-017-6324-2↗
  9. Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction. Co-author DOI 10.1111/cas.12851↗
  10. Nek2 siRNA therapy using a portal venous port-catheter system for liver metastasis in pancreatic cancer. Co-author DOI 10.1111/cas.12993↗
  11. Antitumor effects of α-bisabolol against pancreatic cancer. Last author DOI 10.1111/j.1349-7006.2011.02082.x↗

Closest collaborators

The 25 strongest of 65 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yukihiro Yokoyama · 5 shared papers, 2011–2020 · strength 0.33
  2. Katsuhiko Uesaka · 3 shared papers, 2018–2022 · strength 0.28
  3. Masamichi Hayashi · 3 shared papers, 2018–2020 · strength 0.24
  4. Suguru Yamada · 3 shared papers, 2018–2020 · strength 0.24
  5. Junpei Yamaguchi · 3 shared papers, 2018–2020 · strength 0.24
  6. Yasuhiro Kodera · 3 shared papers, 2018–2020 · strength 0.24
  7. Tsutomu Fujii · 3 shared papers, 2018–2020 · strength 0.24
  8. Shinichiro Takahashi · 2 shared papers, 2018–2022 · strength 0.20
  9. Motohiro Kojima · 2 shared papers, 2018–2022 · strength 0.20
  10. Hirochika Toyama · 2 shared papers, 2020–2022 · strength 0.20
  11. Soichiro Morinaga · 2 shared papers, 2020–2022 · strength 0.20
  12. Satoshi Hirano · 2 shared papers, 2020–2022 · strength 0.20
  13. Yukio Ando · 3 shared papers, 2016–2019 · strength 0.19
  14. Osamu Maeda · 3 shared papers, 2016–2019 · strength 0.19
  15. Fuminori Sonohara · 2 shared papers, 2019–2020 · strength 0.18
  16. Yukiyasu Okamura · 2 shared papers, 2018–2020 · strength 0.17
  17. Hidemi Goto · 2 shared papers, 2018–2019 · strength 0.13
  18. Nao Takano · 2 shared papers, 2018–2019 · strength 0.13
  19. Shinji Naganawa · 2 shared papers, 2018–2019 · strength 0.13
  20. Hiroki Kawashima · 2 shared papers, 2018–2019 · strength 0.13
  21. Yoshiki Hirooka · 2 shared papers, 2018–2019 · strength 0.13
  22. Seiji Natsume · 1 shared paper, 2022 · strength 0.12
  23. Kazuo Hara · 1 shared paper, 2022 · strength 0.12
  24. Shoji Kawakatsu · 1 shared paper, 2022 · strength 0.12
  25. Waki Hosoda · 1 shared paper, 2022 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.